Objective
Dengue virus (DENV) is the most prevalent arthropod-borne viral pathogen and infects about 400 million people worldwide
every year, causing epidemics that are spreading rapidly, with increased frequency and magnitude. To date, no specific
treatments or a fully protective vaccine are available for dengue. In line with the Priority 3 of H2020, the development of
effective therapeutic strategies against DENV is urgently needed. The purpose of FINDER is that of developing innovative
anti-dengue candidate drugs able to disrupt the protein-protein interactions between the viral NS3 and NS5 proteins, two key
and conserved enzymes of DENV replication complex. To this end, some druggable cavities at the NS3/NS5 interface will be
identified and an in silico screening of a virtual small molecule library will be performed to search for potential inhibitors of
NS3/NS5 interaction. After the selection and the biological characterization of the hits, a hit-to-lead optimization step will be
carried out to find compounds with lead-like properties. Such drugs are expected to be endowed with broad-spectrum
antiviral activity, a reduced risk for developing resistance and lower undesirable side-effects. Through a comprehensive
dissemination and exploitation strategy, one or more drug candidates will be evaluated in the future in animal models and
then in clinical trials. The outcomes of this project could fill the gap of the lack of effective anti-DENV drugs, resulting in an
enormous impact on world-wide public health, as well as on the European competitiveness in this area. This project will also
contribute to strengthen a wide set of skills of the applicant by a multidisciplinary training in the field of antiviral research,
which will make him ready for attaining a position of independent researcher. In addition, the complementary competencies
between the applicant and the supervisor will allow a two-way transfer of knowledge, leading to a benefit also for the Host
Organisation.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences basic medicine pharmacology and pharmacy drug discovery
- medical and health sciences health sciences infectious diseases RNA viruses
- medical and health sciences health sciences public health
- natural sciences biological sciences biochemistry biomolecules proteins proteomics
- medical and health sciences basic medicine pharmacology and pharmacy pharmaceutical drugs vaccines
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
H2020-EU.1.3. - EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions
MAIN PROGRAMME
See all projects funded under this programme -
H2020-EU.1.3.2. - Nurturing excellence by means of cross-border and cross-sector mobility
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
MSCA-IF-EF-ST - Standard EF
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) H2020-MSCA-IF-2017
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
CF10 3AT CARDIFF
United Kingdom
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.